跳到正文
Advanced Healthcare Materials· Li·· 7 天前AI 评分43

工程化乳源细胞外囊泡整合PCSK9沉默与炎症调控用于高脂血症治疗

Engineered Milk‐Derived Extracellular Vesicles Integrate PCSK9 Silencing and Inflammation Modulation for Hyperlipidemia Therapy

AI 导读

将30.0%(w/w)益生菌来源糖脂掺入乳源细胞外囊泡(MDEs)膜中构建的工程化MDEs,负载PCSK9 siRNA后体外沉默效率达90.2 ± 0.2%,优于未修饰MDEs与常规LNPs。高脂血症小鼠全身给药后血清血脂谱改善、脂质蓄积与全身炎症降低,在所考察条件下安全性良好。该载体平台通过同时降脂与抗炎为高脂血症治疗提供思路。

AI 深度导读基于原文整理的分节解读
背景
高脂血症与慢性炎症相关,需要同时降脂与抗炎的整合策略。PCSK9 siRNA 是核酸降脂的代表,但 GalNAc-siRNA 缺少直接抗炎作用,脂质纳米颗粒(LNPs)则易引发非预期炎症反应。
做法
研究以天然抗炎的乳源细胞外囊泡(MDEs)为载体,但其以内吞途径转运、在内体/溶酶体中滞留较多,限制 siRNA 进入胞质。作者在膜中掺入 30.0%(w/w)益生菌来源糖脂以促进早期内体逃逸,并负载 PCSK9 siRNA。
结论
改造后的 MDEs 沉默效率达 90.2 ± 0.2%,优于未修饰 MDEs 和常规 LNPs。在高脂血症小鼠中全身给药后,血清血脂谱改善、脂质蓄积与全身炎症降低,在所考察条件下安全性良好。原文另提到 MDEs 体外可抑制关键促炎因子 30.0%–96.5%。
意义
该工作提出一种基于工程化 MDEs 的核酸递送平台,试图在降脂的同时发挥抗炎作用。结果主要来自细胞与小鼠层面,向临床推进仍需进一步验证。

原文摘要

出版方登记 · Crossref

Hyperlipidemia is a systemic metabolic disorder closely associated with chronic inflammation. Effective management requires integrated strategies that simultaneously lower lipid level and attenuate inflammation. Nucleic acid therapeutics, such as proprotein convertase subtilisin/kexin type 9 (PCSK9) siRNA, represent a breakthrough in lipid‐lowering therapy. However, they either lack direct anti‐inflammatory effects (GalNAc‐siRNA) or are prone to triggering unintended inflammatory responses themselves such as lipid nanoparticles (LNPs). Milk‐derived extracellular vesicles (MDEs) emerge as naturally anti‐inflammatory nanocarriers that suppress key pro‐inflammatory cytokines by 30.0%–96.5% in vitro. However, MDEs predominantly undergo endocytic trafficking with substantial endosomal/lysosomal sequestration, which can limit productive cytosolic siRNA delivery. To address this, we developed engineered MDEs by incorporating 30.0% ( w/w ) probiotic‐derived glycolipids into their membranes to facilitate early endosomal escape. When loaded with PCSK9 siRNA, the engineered MDEs achieved a remarkable silencing efficiency of 90.2 ± 0.2%, significantly outperforming both unmodified MDEs and conventional LNPs. In hyperlipidemic mice, systemic administration of engineered MDEs improved serum lipid profiles, reduced lipid accumulation and systemic inflammation, and showed a favorable safety profile under the conditions examined. Collectively, this work provides a promising nucleic acid delivery platform based on engineered MDEs for enhanced hyperlipidemia therapy through simultaneous lipid‐lowering and anti‐inflammatory effects.

页面未能读取全文,以上为出版方登记的摘要;方法与图表见原文

本页是 AI 精读,不转载论文原文;完整论文(含方法、图表与参考文献)见原文

来源:Advanced Healthcare Materials · doi.org